Takeda Pharmaceutical reported strong financials for three quarters of fiscal year 2015, from April to December.
Here are four notes:
1. The company's underlying revenue increased by 3.8 percent year-to-year, led by strong performance in the U.S. and the emerging markets
2. It also reported an underlying core earnings increase of 1.5 percent year-to-year.
3. Underlying revenue from the gastroenterology market was up by 24.7 percent year-to-year.
4. Based on performance through three quarters, Takeda raised the full-year reported forecast for operating profit to 120 billion yen.